Ear Fullness: Labs, Diagnosis, and Next Steps

Why Ear Fullness Happens

Aural fullness is a subjective sensation of pressure, blockage, or "stuffiness" in one or both ears. The feeling originates from mechanical obstruction, pressure imbalance across the tympanic membrane, or altered neural signaling in the cochlea or auditory nerve.

The ear's pressure regulation depends on the Eustachian tube, a 36 mm cartilaginous and bony canal connecting the middle ear to the nasopharynx. When this tube fails to open properly during swallowing or yawning, negative middle-ear pressure builds and the tympanic membrane retracts inward 1. A 2015 international consensus panel defined Eustachian tube dysfunction (ETD) as "failure of the Eustachian tube to adequately perform one or more of its functions: pressure regulation, secretion clearance, or protection from nasopharyngeal reflux" 1. ETD is the single most frequent explanation for ear fullness in adults without active infection.

Other mechanisms produce the same symptom through different pathways. Endolymphatic hydrops (the pathologic hallmark of Meniere's disease) distends the membranous labyrinth and generates a low-frequency pressure sensation. Cerumen impaction physically occludes the external canal, dampening sound transmission and creating a plugged feeling. Sudden sensorineural hearing loss (SSNHL) can present with fullness as the only initial complaint before the patient notices hearing change 2. TMJ dysfunction refers pain to the periauricular region through shared trigeminal nerve innervation, producing fullness without any middle- or inner-ear pathology.

Short list. Long differential. That distinction matters because the workup branches sharply depending on which mechanism you suspect.

The Diagnostic Workup: Where to Start

A systematic evaluation begins with history, otoscopy, tympanometry, and audiometry. These four steps identify the cause in the majority of cases without any blood draw or scan.

Otoscopy is the entry point. The clinician inspects the tympanic membrane for retraction, effusion, perforation, or cholesteatoma. A retracted membrane with visible landmarks suggests ETD. An amber or blue-tinged membrane points toward middle-ear effusion. The 2016 AAO-HNS clinical practice guideline on otitis media with effusion recommends pneumatic otoscopy as the primary diagnostic method, noting a sensitivity of 94% and specificity of 80% in trained hands 3.

Tympanometry quantifies middle-ear compliance. A Type B (flat) tracing confirms effusion or perforation. A Type C tracing (negative pressure peak) supports ETD. The test takes less than a minute per ear and requires no patient effort beyond sitting still.

Pure-tone audiometry is non-negotiable when fullness is unilateral or accompanied by hearing change. The AAO-HNS guideline on SSNHL defines sudden hearing loss as a 30 dB or greater sensorineural deficit across three contiguous frequencies, developing within 72 hours 2. Missing this diagnosis within the first 14 days narrows the treatment window for oral or intratympanic corticosteroids.

Decision branch after audiometry: If the audiogram shows conductive loss with Type B tympanogram, the next step is watchful waiting (if acute) or ENT referral (if persistent beyond 3 months). If the audiogram shows sensorineural loss, the clinician should order an MRI of the internal auditory canals with gadolinium to rule out vestibular schwannoma (acoustic neuroma), which accounts for roughly 1 in 100,000 person-years of incidence 4.

When Blood Work Is Actually Needed

Routine lab panels are not part of the standard ear-fullness workup. Blood tests enter the picture only when the history or audiometric pattern suggests a systemic or autoimmune etiology.

The most common scenario prompting lab orders is bilateral or rapidly progressive sensorineural hearing loss in a patient under age 50 without noise exposure history. Autoimmune inner ear disease (AIED) affects an estimated 15 out of every 100,000 people, and lab markers help support the clinical suspicion 5.

Labs to consider:

• CBC with differential. Screens for infection, leukemia, or hematologic conditions that may affect cochlear blood supply.
• ESR and CRP. Nonspecific inflammatory markers; if elevated alongside progressive hearing loss, they support an inflammatory or autoimmune process.
• ANA and anti-dsDNA. Lupus can cause sensorineural hearing loss in 25% to 45% of affected patients according to retrospective series 6.
• Thyroid panel (TSH, free T4). Hypothyroidism is associated with sensorineural hearing loss through reduced cochlear blood flow and myxedematous infiltration of middle-ear structures. A cross-sectional analysis in the National Health and Nutrition Examination Survey found that hypothyroid subjects had significantly worse pure-tone averages than euthyroid controls 7.
• Fasting glucose or HbA1c. Diabetes doubles the risk of hearing loss per a meta-analysis of 13 studies involving 20,194 participants, published in the Journal of Clinical Endocrinology and Metabolism 8.
• RPR or FTA-ABS. Syphilis is a rare but treatable cause of sudden or fluctuating hearing loss; the CDC recommends screening when the clinical picture is otherwise unexplained 9.

Do not order all of these reflexively. A targeted panel based on the patient's age, risk factors, and audiometric pattern avoids unnecessary cost and follow-up.

Meniere's Disease: A Specific Protocol

Meniere's disease deserves its own section because ear fullness is one of its four cardinal symptoms (the others being episodic vertigo, fluctuating sensorineural hearing loss, and tinnitus). The condition affects roughly 200 per 100,000 adults in the United States 10.

The Barany Society and AAO-HNS published consensus diagnostic criteria in 2015: definite Meniere's disease requires at least two spontaneous vertigo episodes lasting 20 minutes to 12 hours, audiometrically documented low- to mid-frequency sensorineural hearing loss in the affected ear on at least one occasion, and fluctuating aural symptoms (fullness, hearing, tinnitus) in the affected ear 10.

Dr. Jose A. Lopez-Escamez, lead author of the 2015 consensus criteria, wrote that "the diagnosis remains clinical, and no single biomarker or imaging finding can confirm or exclude the disease" 10. This means the workup for suspected Meniere's disease relies on serial audiograms documenting fluctuating low-frequency loss, not on a single lab test or scan.

Electrocochleography (ECoG) can support the diagnosis by detecting an elevated summating potential-to-action potential (SP/AP) ratio, with values above 0.40 to 0.50 considered abnormal depending on the laboratory's normative data. MRI with 3D-FLAIR and intratympanic gadolinium injection is an emerging technique that can visualize endolymphatic hydrops directly, though it remains a research tool in most clinical settings 11.

First-line management centers on dietary sodium restriction (below 1,500 to 2 to 000 mg per day), caffeine and alcohol reduction, and a thiazide diuretic or betahistine (widely used outside the United States, where it is not FDA-approved). A Cochrane review of betahistine for Meniere's disease found insufficient high-quality evidence to confirm or deny its effectiveness, though the review noted that most included trials were small and at high risk of bias 12.

Imaging: CT and MRI Indications

Not every patient with ear fullness needs a scan. Imaging is reserved for specific clinical scenarios where the stakes of a missed diagnosis are high.

MRI with gadolinium of the internal auditory canals (IACs) is indicated when:

• Asymmetric sensorineural hearing loss is found on audiometry (a difference of 15 dB or more at two frequencies, or 20 dB at one frequency).
• Unilateral tinnitus accompanies the fullness.
• Vestibular schwannoma must be excluded. These tumors represent about 8% of intracranial neoplasms 4.

The AAO-HNS SSNHL guideline recommends against CT as a first-line imaging study for sensorineural patterns because CT cannot reliably detect soft-tissue lesions of the cerebellopontine angle 2.

High-resolution CT of the temporal bones is appropriate when:

• Conductive hearing loss persists without effusion (suggesting otosclerosis, ossicular discontinuity, or superior semicircular canal dehiscence).
• Cholesteatoma is suspected based on otoscopic findings.
• Chronic otitis media with possible bony erosion is present.

Superior semicircular canal dehiscence syndrome (SCDS) is a specific entity worth knowing. Patients experience fullness, autophony (hearing their own voice or heartbeat amplified), and sound- or pressure-induced vertigo. Diagnosis requires a CT of the temporal bones with 0.5 mm or thinner slices reformatted in the plane of the superior canal. A population-based temporal bone study found radiographic dehiscence in approximately 0.7% of temporal bones, though symptomatic SCDS is far less common 13.

Allergy Testing and Nasal Evaluation

Allergic rhinitis is a frequently overlooked contributor to ear fullness. Mucosal inflammation in the nasopharynx causes Eustachian tube edema and impairs its opening function. The connection is well established: a study published in the American Journal of Rhinology and Allergy found that 85% of patients with confirmed ETD had coexisting allergic rhinitis based on skin-prick testing 14.

When ear fullness is bilateral, seasonal, or accompanied by nasal congestion, sneezing, or postnasal drip, allergy evaluation becomes a practical next step. Options include skin-prick testing (results in 15 to 20 minutes) and serum-specific IgE panels (useful when skin testing is contraindicated by antihistamine use or dermatologic conditions).

Treatment of the underlying allergy often resolves the ear symptom without any ear-specific intervention. Intranasal corticosteroid sprays (fluticasone 50 mcg, mometasone 50 mcg, or triamcinolone 55 mcg, one to two sprays per nostril daily) reduce Eustachian tube mucosal edema. Second-generation oral antihistamines (cetirizine 10 mg, loratadine 10 mg, or fexofenadine 180 mg daily) address the systemic allergic response. The AAO-HNS guideline on otitis media with effusion recommends against antihistamines and decongestants as a treatment for established effusion but does not address their role in ETD without effusion 3.

Nasal endoscopy, performed in-office by an ENT specialist, allows direct visualization of the Eustachian tube orifice, adenoid pad, and nasopharyngeal mucosa. This step is warranted when unilateral fullness persists for more than 3 months, especially in adult smokers, because nasopharyngeal carcinoma (NPC) can obstruct the Eustachian tube. NPC incidence in the United States is low (0.7 per 100,000 per year), but rises sharply in Southeast Asian and Southern Chinese populations 15.

Treatment Pathways by Cause

The treatment for ear fullness depends entirely on which mechanism is responsible. There is no single medication or procedure that addresses all causes.

ETD without effusion. Autoinsufflation techniques (Valsalva maneuver, balloon dilation of the Eustachian tube) and intranasal steroids are first-line. Eustachian tube balloon dilation (ETBD) is an FDA-cleared procedure that showed symptom improvement in 72% of patients at 12 months in a prospective multicenter study 16. ETBD is typically reserved for patients who fail 6 to 12 weeks of medical therapy.

Otitis media with effusion (OME). The 2016 AAO-HNS guideline recommends observation for 3 months before considering tympanostomy tube placement, given that 75% to 90% of residual OME after an acute episode resolves spontaneously within 3 months 3.

Cerumen impaction. Removal by irrigation, curette, or suction. The AAO-HNS cerumen impaction guideline recommends against cotton swabs and ear candling 17.

SSNHL. Oral prednisone 60 mg daily for 10 to 14 days, initiated within 14 days of onset, is the standard initial treatment per the AAO-HNS guideline. For patients who fail oral steroids or have contraindications (uncontrolled diabetes, active infection), intratympanic dexamethasone (10 mg/mL, three to four injections over 2 weeks) is recommended as salvage therapy 2.

TMJ dysfunction. Referral to oral and maxillofacial specialist or physical therapist. Occlusal splints, jaw exercises, and NSAIDs form the initial approach. The ear fullness typically tracks with jaw symptoms and worsens with chewing or clenching.

Meniere's disease. Sodium restriction, diuretics, and vestibular rehabilitation for the acute and inter-episode periods. Intratympanic gentamicin or endolymphatic sac surgery is reserved for medically refractory cases. The Endocrine Society has no direct guideline on Meniere's, but metabolic optimization (glucose control, thyroid function) may influence disease severity.

Red Flags That Require Urgent Action

Certain presentations demand same-day or next-day evaluation. Do not wait weeks for a routine ENT appointment when these features are present.

Sudden unilateral hearing loss with fullness. The AAO-HNS guideline is explicit: "Clinicians should obtain audiometry as soon as possible (within 14 days of symptom onset) in a patient with presumed sudden sensorineural hearing loss" 2. Earlier treatment with corticosteroids correlates with better hearing recovery. A retrospective study of 443 SSNHL patients showed that treatment initiated within 7 days yielded significantly better outcomes than treatment started between days 8 and 14 18.

Pulsatile tinnitus with fullness. This combination raises concern for vascular abnormalities (glomus tumors, dural arteriovenous fistulae, carotid stenosis). MRI/MRA of the head and temporal bones is warranted.

Bloody otorrhea or facial nerve weakness. These findings suggest cholesteatoma with bony erosion, temporal bone fracture, or malignancy. CT of the temporal bones and urgent ENT referral are indicated.

Weight loss, unilateral effusion, and cranial neuropathy in an adult. This triad suggests nasopharyngeal carcinoma until proven otherwise, especially in patients of Southern Chinese, Southeast Asian, or North African descent.

Vertigo lasting more than 24 hours with fullness. While Meniere's episodes typically resolve within 12 hours, persistent vertigo suggests labyrinthitis, stroke, or demyelinating disease. Neuroimaging (MRI brain with diffusion-weighted sequences) should be obtained.

Do not attribute persistent unilateral ear fullness to "stress" or "allergies" without first ruling out retrocochlear pathology through audiometry and, if indicated, MRI. A vestibular schwannoma grows slowly (1 to 2 mm per year on average), and early detection preserves both hearing and facial nerve function.

Building a Follow-Up Plan

Ear fullness that persists beyond 4 weeks despite initial treatment deserves a structured reassessment. Repeat audiometry at 4, 8, and 12 weeks tracks whether hearing is stable, improving, or declining. Tympanometry at each visit confirms or excludes developing effusion. If the initial workup was limited to primary care, an ENT referral at the 4-week mark is reasonable for any unilateral or progressive case.

For patients diagnosed with Meniere's disease, serial audiograms every 3 to 6 months document the trajectory of hearing loss and guide escalation decisions. A decline of 10 dB or more in the pure-tone average over 6 months, despite dietary and medical therapy, may prompt discussion of intratympanic treatment.

Patients with SSNHL who received corticosteroids should have a follow-up audiogram at 2 to 4 weeks to assess recovery. The AAO-HNS guideline categorizes recovery as complete (return to within 10 dB of baseline), partial (improvement of 10 dB or more without full recovery), or no recovery 2. Patients with incomplete recovery at 4 weeks should discuss salvage intratympanic steroids if not already attempted.

A follow-up audiogram at 6 months after SSNHL is the minimum recommended interval for detecting late changes, and annual audiometry is reasonable for any patient with a history of inner-ear pathology.